Form 4: Aquestive Therapeutics Director Santo J. Costa Acquires Stock Options

Director Santo J. Costa acquired 38,000 stock options in Aquestive Therapeutics, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Santo J. Costa, a director of Aquestive Therapeutics, Inc., acquired 38,000 stock options.
• The options have an exercise price of $2.50.
• These options vest on June 20, 2025, contingent upon Mr. Costa's continuous service with the company.
• Mr. Costa directly owns 17,327 shares of Aquestive Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, not an open market purchase.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates